 |
3 Diseases |  |
2 Trials |
|
2 Trials |  |
11 News |  |
- ||| Barycela (varicella II vaccine) / GC Biopharma
Enrollment change: Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination (clinicaltrials.gov) - Jan 23, 2024
P2, N=230, Recruiting, Sponsor: Green Cross Corporation
N=501 --> 230
- | Barycela (varicella II vaccine) / GC Biopharma
Journal: Cross-reactive humoral immunity of clade 2 Oka and MAV/06 strain-based varicella vaccines against different clades of varicella-zoster virus. (Pubmed Central) - May 23, 2023
Nevertheless, the GMTs of the two vaccinated groups for the same strain were not significantly different. These results suggest that both MG1111 and VARIVAX vaccinations induce cross-reactive humoral immunity against other clades of VZV.
- | Varilrix (live attenuated varicella zoster virus vaccine) / GSK, Barycela (varicella II vaccine) / GC Biopharma
Journal: Assessment of attenuation of varicella-zoster virus vaccines based on genomic comparison. (Pubmed Central) - Mar 30, 2023
In particular, attenuation-associated 42 SNPs showed that Barycela, VarilRix, VariVax, and SKY Varicella are in ascending order regarding similarity with pOka-like genotypes, which in turn, might provide genomic evidence for the levels of attenuation. Finally, the phylogenetic network analysis demonstrated that genetic distances from the parental strain correlated with the attenuation levels of the vaccines.
- ||| Barycela (varicella II vaccine) / GC Biopharma
New trial: An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years (clinicaltrials.gov) - Dec 23, 2022
P=N/A, N=250, Not yet recruiting, Sponsor: GC Biopharma Corp
- |||| Barycela (varicella II vaccine) / GC Biopharma
Enrollment open: Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination (clinicaltrials.gov) - Jul 1, 2022
P2, N=501, Recruiting, Sponsor: Green Cross Corporation
Finally, the phylogenetic network analysis demonstrated that genetic distances from the parental strain correlated with the attenuation levels of the vaccines. Not yet recruiting --> Recruiting
- ||||| Barycela (varicella II vaccine) / GC Biopharma
New P2 trial: Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination (clinicaltrials.gov) - Jun 15, 2022
P2, N=501, Not yet recruiting, Sponsor: Green Cross Corporation
- ||| MG1111 / Green Cross
Clinical, P3 data, Journal: Immunogenicity and safety profiles of a new MAV/06 strain varicella vaccine in healthy children: A multinational, multicenter, randomized, double-blinded, active-controlled phase III study. (Pubmed Central) - May 25, 2021
Furthermore, the MG1111 and control vaccine groups were not significantly different in the percentage of participants showing adverse events-solicited, local, or systemic during 43-day period of observation and serious adverse events during 6 month of observation. The present results indicate that MG1111was not immunologically inferior to Varivax, and safety profiles of MG1111 are similar to those of Varivax.
- ||||||| Barycela (varicella II vaccine) / GC Biopharma
Trial completion, Head-to-Head: A Study of MG1111 in Healthy Children (clinicaltrials.gov) - May 14, 2021
P2/3, N=814, Completed, Sponsor: Green Cross Corporation
The present results indicate that MG1111was not immunologically inferior to Varivax, and safety profiles of MG1111 are similar to those of Varivax. Recruiting --> Completed
- |||||||||| Barycela (varicella II vaccine) / GC Biopharma
New P2/3 trial, Head-to-Head: A Study of MG1111 in Healthy Children (clinicaltrials.gov) - Dec 18, 2017
P2/3, N=828, Recruiting, Sponsor: Green Cross Corporation
- | Barycela (varicella II vaccine) / GC Biopharma
Trial completion: Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults (clinicaltrials.gov) - Sep 3, 2015
P1, N=39, Completed, Sponsor: Green Cross Corporation
Recruiting --> Completed Not yet recruiting --> Completed
- | Barycela (varicella II vaccine) / GC Biopharma
New P1 trial: Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults (clinicaltrials.gov) - Feb 20, 2015
P1, N=39, Not yet recruiting, Sponsor: Green Cross Corporation